The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Abstract
Purpose: To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy. Patients and Methods: Two-hundred thirty-three patients (median age, 70 years; range, 60 to 90 years) were enrolled; 53% had poor-risk cytogenetics, and the median MDS duration at random assignment was 3 months. Primary end point was overall survival (OS). Decitabine (15 mg/m 2) was given intravenously over 4 hours three times a day for 3 days in 6-week cycles. Results: OS prolongation with decitabine versus BSC was not statistically significant (median OS, 10.1 v 8.5 months, respectively; hazard ratio [HR], 0.88; 95% CI, 0.66 to 1.17; two-sided, log-rank P = .38). Progression-free survival (PFS), but not acute myeloid leukemia (AML) –free survival (AMLFS), was significantly prolonged with decitabine versus BSC (median PFS, 6.6 v 3.0 months, respectively; HR, 0.68; 95% CI, 0.52 to 0.88; P = .004; median AMLFS, 8.8 v 6.1 months, respectively; HR, 0.85; 95% CI, 0.64 to 1.12; P = .24). AML transformation was significantly (P = .036) reduced at 1 year (from 33% with BSC to 22% with decitabine). Multivariate analyses indicated that patients with short MDS duration had worse outcomes. Best responses with decitabine versus BSC, respectively, were as follows: complete response (13% v 0%), partial response (6% v 0%), hematologic improvement (15% v 2%), stable disease (14% v 22%), progressive disease (29% v 68%), hypoplasia (14% v 0%), and inevaluable (8% v 8%). Grade 3 to 4 febrile neutropenia occurred in 25% of patients on decitabine versus 7% of patients on BSC; grade 3 to 4 infections occurred in 57% and 52% of patients on decitabine and BSC, respectively. Decitabine treatment was associated with improvements in patient-reported quality-of-life (QOL) parameters. Conclusion: Decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL. Short MDS duration was an independent adverse prognosticator.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationEpigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citationEpigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1799 · Cited by 1,639
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685
Cheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Self-citationBurnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
Self-citationDaskalakis, M., Nguyen, T. T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P. A., & Lübbert, M. (2002) · Blood · doi:10.1182/blood.v100.8.2957 · Cited by 514
Self-citationGore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 474
Kornblith, A. B., Herndon, J. E., Silverman, L. R., Demakos, E. P., Odchimar-Reissig, R., Holland, J. F., Powell, B. L., DeCastro, C., Ellerton, J., Larson, R. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.044 · Cited by 419
Steensma, D. P., Baer, M. R., Slack, J. L., Buckstein, R., Godley, L. A., Garcia-Manero, G., Albitar, M., Larsen, J. S., Arora, S., Cullen, M. T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6550 · Cited by 319
Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C. M., & Lübbert, M. (2009) · Leukemia · doi:10.1038/leu.2008.397 · Cited by 315
Self-citationFandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S., & Keating, M. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229
Raj, K. K., John, A. M., Ho, A. Y. L., Chronis, C., Khan, S. N., Samuel, J., Pomplun, S., Thomas, N. S. B., & Mufti, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404796 · Cited by 154
Deschler-Baier, B., de Witte, T., Mertelsmann, R. H., & Lübbert, M. (2006) · PubMed · Cited by 138
Self-citationKantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115
Miller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1993) · Annals of Hematology · doi:10.1007/bf01697631 · Cited by 114
Miller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1992) · Annals of Hematology · doi:10.1007/bf01703109 · Cited by 113
Wijermans, P., Lübbert, M., Verhoef, G. E. G., Klimek, V. M., & Bosly, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0012-1 · Cited by 104
Self-citationHellström‐Lindberg, E., Robèrt, K., Gahrton, G., Lindberg, G., Forsblom, A., Kock, Y., & Öst, Å. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb02982.x · Cited by 76
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Self-citationPlass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3554 · Cited by 453
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Hollenbach, P. W., Nguyen, A. N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S. L., Heise, C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362
Metadata
- Authors
- Lübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H. R., Beeldens, F., Muus, P., Pflüger, K.-H., Coens, C., Hagemeijer, A., Eckart Schaefer, H., Ganser, A., Aul, C., de Witte, T., & Wijermans, P. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-20
- Volume
- 29
- Issue
- 15
- Pages
- 1987-1996
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106082819
- Cited by
- 552
- References
- 24
- FWCI
- 28.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.